retatrutide nejm 2023 obesity trial ly3437943 just posted the biggest weight-loss numbers ever recorded for a drug — 28.3% (≈70 lb) average in Phase 3, with 45% of people hitting 30%+ loss, territory once reserved for bariatric Incretin triple agonist retatrutide (LY3437943)

Supplementary information (PDF 855 kb) Rights and permissions About this article Cite this article Close, AF., Chae, H

What Consumers Should Know About GLP-1 Evidence and FeelGood's Brand-Stated Outcome Claims There are two separate issues consumers should not confuse: the clinical evidence for FDA-approved GLP-1 medications in appropriate patients, and FeelGood's brand-stated outcome claims for its own telehealth program

Retatrutide is a once-weekly injectable medication being studied for significant weight loss

47 While lifestyle modifications, regular physical activity and diet are recommended for all HF patients, weight reduction should be a direct therapy goal for patients with HFpEF and obesity

Available In-Clinic & Mobile $229-$428 The Executive includes Magnesium along with a targeted B complex designed to support focus and calm, steady energy during busy periods